FDA Accepts Obexelimab BLA with May 2027 PDUFA Date; Zenas Reports $673.9M Cash
ZBIO has more than doubled off its 52-week low of $13.5.
Summary
Zenas BioPharma reported Q2 2026 results with $673.9 million in cash and investments, extending runway well beyond the May 2027 PDUFA date. The FDA accepted the obexelimab BLA for IgG4-RD with a target action date of May 27, 2027, a major regulatory milestone. Phase 3 INDIGO data showed a 56% reduction in flare risk and was published in NEJM, strengthening the commercial case. Additional catalysts include Phase 2 SLE topline data in Q4 2026 and initial Phase 1 data for ZB021 by year-end. The CFO transition and board expansion add execution depth ahead of potential commercialization.
At the time of this announcement, ZBIO was trading at $31.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $13.50 to $44.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.